Related Experiment Video
Updated: Feb 10, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers
Emiko Kinoshita-Kikuta1, Eiji Kinoshita1, Sayaka Ueda1
1Department of Functional Molecular Science, Graduate School of Biomedical & Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan.
Abstract:
The kinase MEK1 is an essential component of the mitogen-activated protein kinase cascades. Somatic mutations that have been identified in the MEK1-coding gene generally enhance kinase activity. Consequently, MEK1 has attracted much interest as a target for cancer therapy to block the aberrant activity. By using Phos-tag affinity electrophoresis, we found that the introduction of mutations detected in certain sporadic cancers or in MEK-inhibitor-resistant cancer cells produced constitutively active MEK1 species containing phosphorylated Ser-218 and Ser-222 residues; it also enhanced the constitutive activity of the kinase. Phosphorylation profiling of the mutants in the presence of inhibitors of RAF/MEK demonstrated that several mutations conferred resistance to multiple inhibitors as a result of an increase in the quantity of active MEK1 species containing the two phosphorylated Ser-218 and Ser-222 residues. Phos-tag-based phosphorylation profiling of MEK1 can therefore provide clinical insights into characteristics of individual mutations in the MEK1-coding gene.
Insights
Mutations in the MEK1 gene can enhance its activity, leading to cancer. Phos-tag analysis reveals how these mutations cause resistance to MEK inhibitors, offering insights for targeted cancer therapy.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Mitogen-activated protein kinase (MAPK) cascades are crucial cellular signaling pathways.
- The kinase MEK1 is a key component of these cascades, and its dysregulation through somatic mutations is implicated in various cancers.
- Aberrant MEK1 activity makes it a significant therapeutic target for cancer treatment.
Purpose of the Study:
- To investigate the functional consequences of MEK1 mutations found in sporadic cancers and drug-resistant cell lines.
- To characterize the phosphorylation status and activity of MEK1 mutants using Phos-tag affinity electrophoresis.
- To assess the impact of these mutations on MEK1 inhibitor resistance.
Main Methods:
- Utilized Phos-tag affinity electrophoresis to analyze the phosphorylation status of MEK1.
- Introduced specific MEK1 mutations associated with cancer and drug resistance.
- Performed phosphorylation profiling of MEK1 mutants in the presence of RAF/MEK inhibitors.
Main Results:
- Mutations in MEK1 led to constitutively active forms of the kinase, characterized by phosphorylation at Ser-218 and Ser-222 residues.
- Several MEK1 mutations conferred resistance to multiple MEK inhibitors.
- This resistance was associated with an increased abundance of active, phosphorylated MEK1 species.
Conclusions:
- Phos-tag-based phosphorylation profiling is a valuable tool for understanding MEK1 mutation characteristics.
- The findings provide clinical insights into MEK1-driven cancers and mechanisms of inhibitor resistance.
- This approach can aid in the development of more effective targeted cancer therapies.
Related Concept Videos
Mutations
What is a Species?
Cancers Originate from Somatic Mutations in a Single Cell
Keystone Species
Viral Mutations
Constitutional Isomers of Alkanes
The linear isomer of an alkane is prefixed by the term “n”; hence a linear isomer of pentane is known as n-pentane. Based on the type of branching, some of the...

